Researchers characterized a new entity of non-scarring alopecia, macular alopecia, which is defined by small lesions and spontaneous resolution.

Adolescents with alopecia areata experience a greater effect on quality of life than adults when experiencing 50% or greater scalp hair loss.

She was diagnosed with alopecia areata, an autoimmune condition that disrupts regular hair growth, at just 18 months old and ...

At week 36, 42.4 and 27.4% of patients receiving baricitinib 4mg and baricitinib 2mg, respectively, achieved a SALT score of less than or equal to 20 compared with 4.5% of patients receiving placebo.

TUESDAY, March 18, 2025 (HealthDay News) -- For adolescents with severe alopecia areata (AA), baricitinib is efficacious for hair regrowth, according to a study presented at the annual meeting of ...

How do you see the future of combination therapies, using baricitinib in conjunction with other treatments, for pediatric alopecia areata? As you know, in the real world, we don't have to do ...

1 "With these data, baricitinib is the most well-studied JAK inhibitor in severe alopecia areata, a chronic immune system disorder that can have an especially devastating social and emotional impact ...

42.4% of adolescents with severe alopecia areata who received baricitinib had 80% or more scalp hair coverage after 36 weeks. An expert said it is the largest trial to date studying treatment in ...

Late-breaking results presented at AAD show 80% or more scalp hair coverage at Week 36 in 42.4% of adolescents receiving baricitinib 4 mg Patients treated with baricitinib 4 mg saw significant ...

Late-breaking results presented at AAD show 80% or more scalp hair coverage at Week 36 in 42.4% of adolescents receiving baricitinib 4 mg ...

with severe alopecia areata (AA) treated with once-daily, oral baricitinib 4 mg and 2 mg saw clinically meaningful improvements in hair regrowth on the scalp, eyebrows and eyelashes at Week 36.